Sentry Investment Management LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 9.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 398,028 shares of the biopharmaceutical company’s stock after selling 41,811 shares during the period. Pfizer makes up 0.9% of Sentry Investment Management LLC’s portfolio, making the stock its 17th largest holding. Sentry Investment Management LLC’s holdings in Pfizer were worth $14,440,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Naples Global Advisors LLC boosted its holdings in Pfizer by 5.4% in the 2nd quarter. Naples Global Advisors LLC now owns 33,695 shares of the biopharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 1,712 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in shares of Pfizer by 25.1% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 285,325 shares of the biopharmaceutical company’s stock worth $10,352,000 after acquiring an additional 57,176 shares during the period. Destination Wealth Management lifted its holdings in shares of Pfizer by 962,667.3% during the 2nd quarter. Destination Wealth Management now owns 500,639 shares of the biopharmaceutical company’s stock worth $18,163,000 after acquiring an additional 500,587 shares during the period. Gagnon Securities LLC lifted its holdings in shares of Pfizer by 61.1% during the 1st quarter. Gagnon Securities LLC now owns 14,708 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,581 shares during the period. Finally, Pennsylvania Trust Co lifted its holdings in shares of Pfizer by 10.9% during the 2nd quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock worth $28,127,000 after acquiring an additional 67,151 shares during the period. Institutional investors and hedge funds own 68.64% of the company’s stock.

PFE stock opened at $43.51 on Monday. The company has a market cap of $259.01 billion, a P/E ratio of 16.42, a P/E/G ratio of 2.19 and a beta of 0.88. Pfizer Inc. has a 1 year low of $33.20 and a 1 year high of $45.81. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. The business had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 EPS. As a group, research analysts expect that Pfizer Inc. will post 3 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.13%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.

In other Pfizer news, major shareholder Pfizer Inc purchased 55,556 shares of the firm’s stock in a transaction on Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the transaction, the insider now owns 21,976,484 shares in the company, valued at approximately $395,576,712. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

PFE has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Thursday, October 4th. Morgan Stanley set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, August 29th. Credit Suisse Group upped their price target on shares of Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a report on Wednesday, August 1st. Bank of America upped their price target on shares of Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, August 1st. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $45.00 price target on shares of Pfizer in a report on Tuesday, October 30th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $42.67.

TRADEMARK VIOLATION NOTICE: “Sentry Investment Management LLC Decreases Position in Pfizer Inc. (PFE)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.dailypolitical.com/2018/11/19/sentry-investment-management-llc-decreases-position-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: Debt-To-Equity Ratio

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.